News: GSS Genetic Signatures Expects Sales Of At Least A$21M For Half Year, page-19

to be equivalent to nanosonics GSS should range from $700-800m market cap currently. my reasoning is it should be valued in line with that NAN type of product - machine + cartridge albeit with greater cover use due to cartridge / consumables being compatible with majority high throughput PCR machines

when Covid becomes the new normal I can imagine 'panel' respiratory PCR eg those that are able to test multiple influenzas and Covid in one test should become standard. influenza is still a reportable disease and the Covid reporting will be mandatory /managed pursuant to the surveillance for the foreseeable future at least in line with that scheme

the market share of enteric panel will catapult this small cap to the ASX 200/300